BIOMAT Database Logo BIOMAT Database Logo

Cyclosporine, combination immunosuppression, and posttransplant diabetes mellitus. 1987

J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Department of Surgery, University of Minnesota Hospitals and Clinics.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients.
February 1991, Transplantation proceedings,
J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Posttransplant diabetes mellitus in kidney transplant recipients under tacrolimus immunosuppression.
December 2000, Transplantation proceedings,
J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
May 2006, Transplantation proceedings,
J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Posttransplant Diabetes Mellitus and Immunosuppression Selection in Older and Obese Kidney Recipients.
January 2022, Kidney medicine,
J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Posttransplant diabetes mellitus.
May 2003, Transplantation,
J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
January 2001, Transplantation,
J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Posttransplant diabetes mellitus: a serious complication of immunosuppression in renal allograft recipients.
November 2002, Transplantation proceedings,
J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression.
August 1993, Transplantation proceedings,
J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Posttransplant diabetes mellitus in cyclosporine-treated renal allograft patients: a case-control study.
May 2004, Transplantation proceedings,
J P Boudreaux, and L McHugh, and D M Canafax, and N Asher, and D E Sutherland, and W Payne, and R L Simmons, and J S Najarian, and D S Fryd
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.
March 1984, Science (New York, N.Y.),
Copied contents to your clipboard!